Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III Randomized, Placebo Controlled, Double Blind Study to Evaluate the Effects of Up to 24 Weeks of Low Dose Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia

Next Previous
Trial Profile

A Phase II/III Randomized, Placebo Controlled, Double Blind Study to Evaluate the Effects of Up to 24 Weeks of Low Dose Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Epistaxis; Hereditary haemorrhagic telangiectasia
  • Focus Therapeutic Use
  • Acronyms Paz

Most Recent Events

  • 14 Mar 2025 Planned End Date changed from 1 Oct 2026 to 1 Jul 2026.
  • 14 Mar 2025 Planned primary completion date changed from 30 Sep 2025 to 1 Nov 2025.
  • 14 Mar 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top